Sartorius Stedim Biotech

Equities

DIM

FR0013154002

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris 03:51:56 18/07/2024 pm IST 5-day change 1st Jan Change
176.8 EUR +1.99% Intraday chart for Sartorius Stedim Biotech +4.54% -26.47%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Markets Powered by Alternating Current Our Logo
Mixed feelings Our Logo
Oddo BHF Upgrades Sartorius Stedim Biotech to Outperform from Neutral, Lowers PT MT
Sartorius recovers 15 percent from annual low - Oddo recommendation DP
Sartorius further stabilized DP
SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays ZD
The same old winners Our Logo
Sartorius stabilizes after previous day's price slide DP
Sartorius on the downswing again - low since 2020 is approaching DP
SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%) Alphavalue
Sartorius sinks again towards year low DP
Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day
Certain Shares of Sartorius Stedim Biotech S.A. are subject to a Lock-Up Agreement Ending on 8-MAY-2024. CI
SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating ZD
Sartorius Stedim: in the red with brokerage comments CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss Alphavalue
SARTORIUS STEDIM : UBS reduces target price CF
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... Our Logo
Transcript : Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024
Transcript : Sartorius Aktiengesellschaft, Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024
Sartorius and subsidiary Stedim under pressure after weak figures DP
Europe in the green, corporate results hailed RE
Sartorius Stedim: Quarterly EPS more than halved CF
Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chart Sartorius Stedim Biotech
More charts
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
173.4 EUR
Average target price
237.3 EUR
Spread / Average Target
+36.91%
Consensus
  1. Stock Market
  2. Equities
  3. DIM Stock
  4. News Sartorius Stedim Biotech
  5. Sartorius Stedim Biotech : Disappointing preliminary Q3 23 puts mid-term outlook in question